BioMedNewsBreaks

ThursdayFeb 09, 2023 11:35 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Canada. That letter and what it means was the focus of a recent InvestmentPitch Media video. In the video, InvestmentPitch Media’s Cassandra Bolinski discusses the company’s recent receipt of the letter, which provides regulatory approval for FSD Pharms to move forward with its phase 1 clinical trial of LUCID-21-302 or Lucid-MS. A novel drug candidate for the treatment of multiple…

Continue Reading

WednesdayFeb 08, 2023 2:24 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Pushing Boundaries of Innovation

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, developed GPS SmartSole(R), a medical monitoring device integrated into an orthotic insole, facilitating discreet tracking and remote monitoring of those living with Alzheimer’s, dementia and autism, who have a tendency to wander and become lost. “The SmartSole enables tracking by utilizing a 4G cellular network and … can be configured to send alerts via email or text whenever someone enters or exits specific areas, giving caregivers the utmost peace of mind. MetAlert has further enhanced the capabilities of SmartSole by adding Wi-Fi and Bluetooth capabilities, creating…

Continue Reading

WednesdayFeb 08, 2023 12:47 pm

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program

BioRestorative Therapies (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem(R) program. “Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the company’s CEO. “We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem developed by BioRestorative’s scientists, enhances our ability…

Continue Reading

WednesdayFeb 08, 2023 11:16 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate in a question-and-answer session. Interested parties should visit https://ibn.fm/iVpOP to register for the webinar. To view the full press release, visit https://ibn.fm/xstH7 About India Globalization Capital Inc. IGC develops advanced cannabinoid-based formulations for treating diseases…

Continue Reading

TuesdayFeb 07, 2023 1:53 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar and chronic pain,” a recent article reads. “In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a…

Continue Reading

TuesdayFeb 07, 2023 12:13 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward with its proposed phase 1 clinical trial in Canada. The notification came in the form of a No Objection Letter (“NOL”) from Health Canada. The letter gives FSD Pharma regulatory approval to proceed with its clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of multiple sclerosis. The first-in-human clinical trial is designed to evaluate the safety…

Continue Reading

TuesdayFeb 07, 2023 11:59 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first patient in Spain. As part of the trial, the company has opened 37 of 59 planned clinical trial sites; the sites are located in the United States, Italy, France, Spain and Switzerland. The company noted that it plans an interim analysis of the study when…

Continue Reading

MondayFeb 06, 2023 2:00 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis Capital Corp. The update reflects the strong results from BVXV’s latest animal study indicating that anti-COVID-19 NanoAb can prevent infection. According to the report, BiondVax reported that in a continuation of the study, COVID-19 illness was virtually prevented in hamsters that received BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2. The report noted that data gathered from the preclinical trial show that BiondVax’s…

Continue Reading

FridayFeb 03, 2023 12:34 pm

BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Distinctive Solutions Positioned to Transform the Way Patients, Doctors Detect Heart Attacks

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack, and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection… The company anticipates receiving regulatory approval soon for the use of the HeartBeam…

Continue Reading

FridayFeb 03, 2023 11:51 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The  company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin and those receiving Lomustine… Berubicin’s performance in an initial safety trial conducted by another company in 2006 resulted in apparent life extension for some patients and complete remission for one patient who, unusually, survives nearly 17 years later. The ongoing study now seeks to demonstrate…

Continue Reading